[Conversion from +Sandimmune to Neoral in kidney transplant recipients treated with cyclosporine and ketoconazole]. 1997

C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
Unidad de Nefrologíia, Servicio de Medicina Hospital Gustavo Fricke de Viña del Mar, Chile.

BACKGROUND Microemulsion cyclosporine is a new pharmaceutical form whose intestinal absorption is more constant, resulting in a better bioavailability. OBJECTIVE To assess dose adjustments and variability of blood levels after the conversion of cyclosporine to microemulsion cyclosporine in renal transplant recipients function receiving cyclosporine-ketoconazole. METHODS Thirty four patients with more than one year after the transplantation, with stable renal function and receiving triple immunosuppression were studied. Conventional cyclosporine was changed to the microemulsion form maintaining the same daily dose. Drug serum levels, serum creatinine and blood pressure were measured within two to eight months after the conversion. Doses of microemulsion cyclosporine were adjusted to achieve serum levels of 150 +/- 40 ng/ml. RESULTS Microemulsion cyclosporine induced a slight initial increase in blood cyclosporine levels. Afterwards, levels were more stable than with conventional cyclosporine (165-185 and 145-210 ng/ml respectively) and the dispersion of values were lower (standard deviations of 70 and 100 ng/ml respectively). Twenty three patients did not require dose adjustments, in four it was reduced and in five it was increased. There were no changes in serum creatinine or blood pressure after the conversion. CONCLUSIONS More stable serum levels without adverse reactions were obtained with microemulsion cyclosporine. Doses of cyclosporine need not to be changed during the conversion.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007654 Ketoconazole Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Nizoral,R-41400,R41,400,R41400,R 41400
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004655 Emulsions Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES. Emulsion
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
December 1998, Journal of transplant coordination : official publication of the North American Transplant Coordinators Organization (NATCO),
C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
August 1996, Transplantation proceedings,
C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
August 1996, Transplantation proceedings,
C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
January 1997, Transplantation proceedings,
C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
August 1996, Transplantation proceedings,
C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
June 1999, Transplantation proceedings,
C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
August 1998, Transplantation proceedings,
C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
August 1998, Transplantation proceedings,
C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
August 1996, Transplantation proceedings,
C Videla, and J Vega, and H Borja, and A Gatica, and R Clavero, and T Aldunate
August 1998, Transplantation proceedings,
Copied contents to your clipboard!